Navigation Links
Inovio Pharmaceuticals CEO Receives 2013 Drug Discovery & Achievement Award
Date:11/13/2013

ion technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2012, our Form 10-Q for the quarter ended September 30, 2013, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

CONTACTS:
Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101 bhertel@inovio.com 
Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@i
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology news :

1. MVI and Inovio partner to develop malaria vaccines using innovative vaccine delivery tech
2. Scripps Research announces research & license agreement with Janssen Pharmaceuticals
3. Scripps Research and Takeda Pharmaceuticals announce expanded research collaboration
4. Sanford-Burnham and 60° Pharmaceuticals to pursue promising target for the treatment of dengue fever
5. Combination of two pharmaceuticals proves effective in the treatment of multiple sclerosis
6. Conatus Pharmaceuticals Appoints Mark F. Morris as Head of Biostatistics
7. AcelRx Pharmaceuticals Receives First U.S. Patent for Small-Volume Oral Transmucosal Dosage Forms
8. Fish show autism-like gene expression in water with psychoactive pharmaceuticals
9. Tokai Pharmaceuticals galeterone well-tolerated in patients with advanced prostate cancer
10. From scourge to saint: E. coli bacteria becomes a factory - to make cheaper, faster pharmaceuticals
11. Sanford-Burnham receives US Air Force grant to perform next-generation toxicity screens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... disease that exists as five strains, none of which ... is the Sudan ebolavirus (SUDV). Although not the strain ... even as recently as 2012. In a new study ... researchers now report a possible therapy that could someday ... Sachdev Sidhu, Jonathan Lai and colleagues explain that about ...
(Date:8/27/2014)... basic research, a growing focus on translating discoveries ... have earned the Herbert Irving Comprehensive Cancer Center ... NewYork-Presbyterian Hospital an $18 million, five-year Cancer Center ... The grant renews the center,s status as one ... New York City and one of only three ...
(Date:8/27/2014)... shown that excessive iron is closely associated ... studies from Chunyan Guo and co-workers from ... that baicalin prevented iron accumulation after substantia ... expression, and increased ferroportin 1 expression in ... rats. However, the relationship between iron concentration ...
Breaking Biology News(10 mins):Potential therapy for the Sudan strain of Ebola could help contain some future outbreaks 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4
... the brain, cells called neurons go through a cycle ... Fernando Nottebohm, Ph.D., shows that these replaceable neurons share ... people with diseases such as Alzheimer's and Parkinson's: both ... , "It would be ironic if the shortfall in ...
... the vertebrate embryo - the establishment of a back ... - turns out to be so important that the ... it happens properly. , The discovery, reported this month ... University of California, Berkeley, finally explains an 80-year-old observation ...
... a major domain of telomerase, the enzyme that helps maintain ... that act as protective caps -- allowing DNA ends to ... the first major piece of telomerase for which the structure ... and this work ultimately may lead to targets for drug ...
Cached Biology News:One gene links newborn neurons with those that die in diseases such as Alzheimer's 2One gene links newborn neurons with those that die in diseases such as Alzheimer's 3One gene links newborn neurons with those that die in diseases such as Alzheimer's 4Scientists discover that three overlapping signals in embryo help get the backbone right 2Scientists discover that three overlapping signals in embryo help get the backbone right 3Scientists discover that three overlapping signals in embryo help get the backbone right 4Scientists discover that three overlapping signals in embryo help get the backbone right 5Biochemists report discovery of structure of major piece of telomerase; implications for cancer 2Biochemists report discovery of structure of major piece of telomerase; implications for cancer 3
(Date:8/27/2014)... Flagship Biosciences LLC, a leading provider of ... medical device industries, has announced a laboratory and office ... consolidated its histology and tissue analysis operations from separate ... north of Denver. The new addresses are: , ... 100, Westminster, CO 80021 , Tissue Image Analysis Lab, ...
(Date:8/27/2014)... 2014  ARCH Venture Partners, one of the ... development of seed and early-stage advanced technology companies, ... with more than $400 million in subscriptions. ARCH ... target by more than $150 million. ... and potential of our approach to finding and ...
(Date:8/27/2014)... Boca Raton, FL (PRWEB) August 27, 2014 ... that are applied through the use of a handheld ... consumers across the United States. , The brand ... care unit. BIOEQUA researchers were surprised to learn that ... to be made extremely small and delivered directly to ...
(Date:8/27/2014)... Remcom announces an update to XFdtd® ... the biomedical industry. The central biomedical addition in ... to the Bio-Pro version of the software. XFdtd ... calculate the biological effects of electromagnetic fields. In ... versions to expand engineers’ post-processing options. , The Biological ...
Breaking Biology Technology:Flagship Biosciences Announces Relocation and Expansion 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3BIOEQUA'S EQUA ESSENTIAL Product Line Redefines Skin Care & Now Available in America 2Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 2Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 3
... ,Kidney-Friendly, Recipes, HOUSTON, Dec. 7 Celebrity ... SHPGY ), the global biopharmaceutical,company, today announced that ... the Doubletree Hotel Houston Downtown from 1-3 PM,tomorrow, ... kidney,disease (CKD) and their families., During the ...
... Tutogen Medical, Inc.,(Amex: TTG ), a leading manufacturer ... animal (xenograft) tissue, will report,financial results for the fourth ... December 10, 2007 at 4:30 p.m. ET., Interested ... or,(706) 679-5064 or by accessing the web cast at, ...
... Group in North America with this Elevated Partner ... ... an Oracle System,Integrator, today announced it has achieved Oracle Certified Advantage,Partner status ... the highest level in the Oracle PartnerNetwork -- BIAS had,to demonstrate superior ...
Cached Biology Technology:Katie Lee Joel to Conduct Free, Hands-On, Holiday Cooking Demonstration for Local Patients With Chronic Kidney Disease 2Katie Lee Joel to Conduct Free, Hands-On, Holiday Cooking Demonstration for Local Patients With Chronic Kidney Disease 3Katie Lee Joel to Conduct Free, Hands-On, Holiday Cooking Demonstration for Local Patients With Chronic Kidney Disease 4Katie Lee Joel to Conduct Free, Hands-On, Holiday Cooking Demonstration for Local Patients With Chronic Kidney Disease 5Katie Lee Joel to Conduct Free, Hands-On, Holiday Cooking Demonstration for Local Patients With Chronic Kidney Disease 6Katie Lee Joel to Conduct Free, Hands-On, Holiday Cooking Demonstration for Local Patients With Chronic Kidney Disease 7Tutogen Medical, Inc. to Report Fourth Quarter and Fiscal Year 2007 Financial Results 2BIAS Achieves Certified Advantage Partner Level in Oracle PartnerNetwork 2BIAS Achieves Certified Advantage Partner Level in Oracle PartnerNetwork 3
Collected from 8-12 week old sexually mature rats. Pricing: $100/unit for 1 - 10 units...
PlusOne Acrylamide PAGE, 1 kg. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Gel Casting Chemicals....
... The RiboGreen RNA Quantitation Kit is ... systems for the quantitation of RNA ... approximately 1000-fold more sensitive than absorbance ... can be detected with fluorescence microplate ...
... GenoStat Inducible Expression System provides tightly regulated ... cells and is capable of repeated on/off ... mediated by the highly specific interaction between ... nuclear receptor complex. Gene expression levels are ...
Biology Products: